Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 7, 2010, Pages 1279-1284

  Berger, William ^a,b,c   Mehra, Akhil ^a   Lenoci, Maryann ^b   Metzler, Thomas J ^a,b   Otte, Christian ^a,d   Tarasovsky, Gary ^b   Mellon, Synthia H ^a   Wolkowitz, Owen M ^a   Marmar, Charles R ^a,b,e   Neylan, Thomas C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BDNF; Biomarker; Escitalopram; Posttraumatic stress disorders; Predictor of response

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ESCITALOPRAM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MALE; POSTTRAUMATIC STRESS DISORDER; PREDICTION; PROTEIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; SCORING SYSTEM; TREATMENT DURATION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHRONIC DISEASE; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; STRESS DISORDERS, POST-TRAUMATIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956449850     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.07.008     Document Type: Article

References (60)

1. Adachi M., Barrot M., Autry A.E., Theobald D., Monteggia L.M. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008, 63:642-649.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatry Press, Washington, DC. 4th ed. Revised.
3. Aydemir C., Yalcin E.S., Aksaray S., Kisa C., Yildirim S.G., Uzbay T., et al. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1256-1260.
4. Bachis A., Mallei A., Cruz M.I., Wellstein A., Mocchetti I. Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neuropharmacology 2008, 55:1114-1120.
5. Begliuomini S., Lenzi E., Ninni F., Casarosa E., Merlini S., Pluchino N., et al. Plasma brain-derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm. J Endocrinol 2008, 197:429-435.
6. Berger W., Mendlowicz M.V., Marques-Portella C., Kinrys G., Fontenelle L.F., Marmar C.R., et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:169-180.
7. Berton O., McClung C.A., Dileone R.J., Krishnan V., Renthal W., Russo S.J., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006, 311(5762):864-868.
8. Blake D.D., Weathers F.W., Nagy L.M., Kaloupek D.G., Gusman F.D., Charney D.S., et al. The development of a clinician-administered PTSD scale. J Trauma Stress 1995, 8:75-90.
9. Blanchard E.B., Jones-Alexander J., Buckley T.C., Forneris C.A. Psychometric properties of the PTSD checklist (PCL). Behav Res Ther 1996, 34:669-673.
10. Boldrini M., Underwood M.D., Hen R., Rosoklija G.B., Dwork A.J., John Mann J., et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009, 34:2376-2389.
11. Brady K., Pearlstein T., Asnis G.M., Baker D., Rothbaum B., Sikes C.R., et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000, 283:1837-1844.
12. Broekman B.F.P., Olff M., Boer F. The genetic background to PTSD. Neurosci Biobehav Rev 2007, 31:348-362.
13. Brown H., Prescott R. Applied mixed models in medicine 1999, J. Wiley & Sons, New York.
14. Bryant R.A., Felmingham K., Kemp A., Das P., Hughes G., Peduto A., et al. Amygdala and ventral anterior cingulate activation predicts treatment response to cognitive behaviour therapy for post-traumatic stress disorder. Psychol Med 2008, 38:555-561.
15. Creamer M., Burgess P., McFarlane A.C. Post-Traumatic Stress Disorder: findings from The Australian National Survey of Mental Health and Well-Being. Psychol Med 2001, 31:1237-1247.
16. Davidson J.R.T., Rothbaum B.O., Van der Kolk B.A., Sikes C.R., Farfel G.M. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001, 58:485-492.
17. Dell'Osso L., Carmassi C., Del Debbio A., Dell'Osso M.C., Bianchi C., da Pozzo E., et al. Brain-derived neurotrophic factor plasma levels in patients suffering from post-traumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:899-902.
18. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
19. Eisch A.J., Bolanos C.A., de Wit J., Simonak R.D., Pudiak C.M., Barrot M., et al. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol Psychiatry 2003, 54(10):994-1005.
20. Etkin A., Pittenger C., Polan H.J., Kandel E.R. Toward a neurobiology of psychotherapy: basic science and clinical applications. J Neuropsychiatry Clin Neurosci 2005, 17:145-158.
21. Evans K., Dougherty D., Pollack M., Rauch S. Using neuroimaging to predict treatment response in mood and anxiety disorders. Ann Clin Psychiatry 2006, 18:33-42.
22. Felmingham K., Williams L.M., Whitford T.J., Falconer E., Kemp A.H., Peduto A., et al. Duration of posttraumatic stress disorder predicts hippocampal grey matter loss. NeuroReport 2009, 20:1402-1406.
23. First M., Spitzer R.I., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders patient edition 1996, Biometrics Research institute, New York State Psychiatric Institute, New York.
24. Gibbons R.D., Hedeker D., Elkin I., Waternaux C., Kraemer H.C., Greenhouse J.B., et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH Treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993, 50:739-750.
25. Gould E., McEwen B.S., Tanapat P., Galea L.A., Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci 1997, 17:2492-2498.
26. Gould E., Tanapat P., McEwen B.S., Flugge G., Fuchs E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci USA 1998, 95:3168-3171.
27. Graham D.L., Krishnan V., Larson E.B., Graham A., Edwards S., Bachtell R.K., et al. Tropomyosin-related kinase B in the mesolimbic dopamine system: region-specific effects on cocaine reward. Biol Psychiatry 2009, 65:696-701.
28. Grassi-Oliveira R., Stein L.M., Lopes R.P., Teixeira A.L., Bauer M.E. Low plasma brain-derived neurotrophic factor and childhood physical neglect are associated with verbal memory impairment in major depression-a preliminary report. Biol Psychiatry 2008, 64:281-285.
29. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
30. Hashimoto K., Shimizu E., Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Rev 2004, 45:104-114.
31. Hauck S., Gomes F., de Moura Silveira E., Almeida E., Possa M., Ceitlin L.H.F. Serum levels of brain-derived neurotrophic factor in acute and posttraumatic stress disorder: a case report study. Rev Bras Psiquiatr 2009, 31:48-51.
32. Hauck S., Kapczinski F., Roesler R., de Moura Silveira E., Magalhães P.V., Kruel L.R.P., et al. Serum brain-derived neurotrophic factor in patients with trauma psychopathology. Prog in Neuropsychopharmacology. Biol Psychiatry 2010, 34:459-462.
33. Hellweg R., Ziegenhorn A., Heuser I., Deuschle M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Phamacopsychiatry 2008, 41:66-71.
34. Insel T.R., Fernald R.D. How the brain processes social information: searching for the social brain. Annu Rev Neurosci 2004, 27:697-722.
35. Jayatissa M.N., Bisgaard C., Tingström A., Papp M., Wiborg O. Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression. Neuropsychopharmacology 2006, 31:2395-2404.
36. Kafitz K.W., Rose C.R., Thoenen H., Konnerth A. Neurotrophin-evoked rapid excitation through TrkB receptors. Nature 1999, 401:918-921.
37. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002, 109:143-148.
38. Karege F., Schwald M., Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002, 328:261-264.
39. Karege F., Bondolfi G., Gervasoni N., Schwald M., Aubry J.M., Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005, 57:1068-1072.
40. Karl A., Schaefer M., Malta L.S., Dörfel D., Rohleder N., Werner A. A meta-analysis of structural brain abnormalities in PTSD. Neurosci Biobehav Rev 2006, 30:1004-1031.
41. Kauer-Sant'Anna M., Tramontina J., Andreazza A.C., Cereser K., da Costa S., Santin A., et al. Traumatic life events in bipolar disorder: impact on BDNF levels and psychopathology. Bipolar Disord 2007, 9:128-135. Supplement.
42. Kessler R.C., Sonnega A., Bromet E., Hughes M., Nelson C.B. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995, 52:1048-1060.
43. Küçükibrahimoglu E., Saygm M.Z., Çahskan M., Kaplan O.K., Ünsal C., Gören M.Z. The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. Eur J Clin Pharmacol 2009, 65:571-577.
44. Lee B.H., Kim H., Park S.H., Kim Y.K. Decreased plasma BDNF level in depressive patients. J Affect Disord 2007, 101:239-244.
45. Lie D.C., Song H.J., Colamarino S.A., Ming G.L., Gage F.H. Neurogenesis in the adult brain: new strategies for central nervous system diseases. Annu Rev Pharmacol Toxicol 2004, 44:399-421.
46. Lindsay R.M., Wiegand S.J., Altar C.A., DiStefano P.S. Neurotrophic factors: from molecule to man. Trends Neurosci 1994, 17:182-190.
47. Lommatzsch M., Zingler D., Schuhbaeck K., Schloetcke K., Zingler C., Schuff-Werner P., et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005, 26:115-123.
48. Magarinos A.M., McEwen B.S. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience 1995, 69:89-98.
49. Matrisciano F., Bonaccorso S., Ricciardi A., Scaccianoce S., Panaccione I., Wang L., et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 2009, 43:247-254.
50. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry 2002, 51:775-787.
51. Piccinni A., Marazziti D., Del Debbio A., Bianchi C., Roncaglia I., Mannari C., et al. Diurnal variation of plasma Brain-Derived Neurotrophic Factor (BDNF) in humans: an analysis of sex differences. Chronobiol Int 2008, 25:819-826.
52. Robert S., Hamner M.B., Ulmer H.G., Lorberbaum J.P., Durkalski V.L. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry 2006, 67:1522-1526.
53. Rosenberg D.R., MacMaster F.P., Keshavan M.S., Fitzgerald K.D., Stewart C.M., Moore G.J. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000, 39:1096-1103.
54. Sen S., Duman R., Sanacora G. Serum Brain-Derived Neurotrophic Factor, Depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008, 64:527-532.
55. Speer D.C. Clinically significant change: Jacobson and Truax (1991) revisited. J Consult Clin Psychol 1992, 60:402-408.
56. Vega S.R., Strüder H.K., Wahmann B.V., Schmidt A., Bloch W., Hollmann W. Acute BDNF and cortisol response to low intensity exercise and following ramp incremental exercise to exhaustion in humans. Brain Res 2006, 1121:59-65.
57. Vermetten E., Vythilingam M., Southwick S.M., Charney D.S., Bremner J.D. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry 2003, 54:693-702.
58. Vinogradov S., Fisher M., Holland C., Shelly W., Wolkowitz O., Mellon S.H. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?. Biol Psychiatry 2009, 66:549-553.
59. Wang Z., Neylan T.C., Mueller S.G., Lenoci M., Truran D., Marmar C.R., et al. Magnetic resonance imaging of hippocampal subfields in posttraumatic stress disorder. Arch Gen Psychiatry 2010, 67:296-303.
60. Yehuda R. Post-traumatic stress disorder. N Engl J Med 2002, 346:108-114.